HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5‐FU resistance by a p53‐dependent pathway. Issue 6 (27th February 2018)

• Record Type: Journal Article
• Authors: Han, Yang; Song, Chenlong; Wang, Jianying; Tang, Huamei; Peng, Zhihai; Lu, Su
• Is Part Of: Molecular carcinogenesis. Volume 57:Issue 6(2018)
• Page Start: 722
• Page End: 734
• Publication Date: 2018-02-27
• Subjects: chemoresistance -- DHRS2 -- gastric cancer -- HOXA13 -- p53; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.22793
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract : 5‐FU‐based chemotherapy is recently most recommended as the first‐line treatment for gastric cancer (GC). However, 5‐FU resistance is common for many postoperative GC patients. Homeobox A13 (HOXA13) is a member of homeobox genes highly expressed in many human tumors. Its potential roles and mechanisms of resistance to 5‐FU in GC are poorly understood. In this study, we discovered that HOXA13 played an oncogenic role in vivo and in vitro. The patients with HOXA13 overexpression were closely related with poor prognosis and more prone to be resistant to 5‐FU. Moreover, dehydrogenase/reductase 2 (DHRS2) was identified as a downstream gene of HOXA13. HOXA13 played a role of carcinogenesis through directly down‐regulating DHRS2 to increase MDM2. Furthermore, HOXA13 conferred 5‐FU resistance through MRP1 by a p53‐dependent pathway. Therefore, HOXA13 might serve as a potential signature that recognized patients who were insensitive to 5‐FU, and timely recommended them to other chemotherapy regimens.